O	0	9	Increased
O	10	16	breast
O	17	23	cancer
O	24	33	screening
O	34	37	and
O	38	49	downstaging
O	50	52	in
O	53	62	Colombian
O	63	68	women
O	68	69	:
O	70	71	A
O	72	82	randomized
O	83	88	trial
O	89	91	of
B-intervention	92	105	opportunistic
I-intervention	106	112	breast
I-intervention	112	113	-
I-intervention	113	122	screening
O	122	123	.

O	124	127	The
O	128	132	lack
O	133	135	of
O	136	142	breast
O	143	149	cancer
O	150	159	screening
O	160	162	in
O	163	166	low
O	167	170	and
O	171	177	middle
O	177	178	-
O	178	184	income
O	185	194	countries
O	195	202	results
O	203	205	in
O	206	211	later
O	212	217	stage
O	218	227	diagnosis
O	228	231	and
O	232	240	worsened
O	241	249	outcomes
O	250	253	for
O	254	259	women
O	259	260	.

O	261	262	A
O	263	270	cluster
O	271	281	randomized
O	282	287	trial
O	288	291	was
O	292	301	performed
O	302	304	in
B-location	305	310	Bogot
I-location	310	311	รก
I-location	311	312	,
I-location	313	321	Colombia
O	322	329	between
O	330	334	2008
O	335	338	and
O	339	343	2012
O	344	346	to
O	347	355	evaluate
O	356	363	effects
O	364	366	of
O	367	380	opportunistic
O	381	387	breast
O	388	394	cancer
O	395	404	screening
O	404	405	.

O	406	414	Thirteen
O	415	422	clinics
O	423	427	were
O	428	438	randomized
O	439	441	to
O	442	444	an
O	445	457	intervention
O	458	461	arm
O	462	465	and
O	466	468	13
O	469	471	to
O	472	473	a
O	474	481	control
O	482	485	arm
O	485	486	.

O	487	497	Physicians
O	498	500	in
O	501	513	intervention
O	514	521	clinics
O	522	526	were
O	527	537	instructed
O	538	540	to
O	541	548	perform
O	549	557	clinical
O	558	564	breast
O	565	576	examination
O	577	579	on
O	580	583	all
O	584	589	women
O	590	594	aged
B-age	595	597	50
I-age	597	598	-
I-age	598	600	69
I-age	601	606	years
B-eligibility	607	616	attending
I-eligibility	617	624	clinics
I-eligibility	625	628	for
I-eligibility	629	632	non
I-eligibility	632	633	-
I-eligibility	633	639	breast
I-eligibility	640	646	health
I-eligibility	647	653	issues
O	653	654	,
O	655	658	and
O	659	663	then
O	664	669	refer
O	670	674	them
O	675	678	for
O	679	691	mammographic
O	692	701	screening
O	701	702	.

O	703	713	Physicians
O	714	716	in
O	717	724	control
O	725	732	clinics
O	733	737	were
O	738	741	not
O	742	752	explicitly
O	753	763	instructed
O	764	766	to
O	767	774	perform
O	775	781	breast
O	782	791	screening
O	792	794	or
O	795	806	mammography
O	807	816	referrals
O	816	817	,
O	818	821	but
O	822	827	could
O	828	830	do
O	831	833	so
O	834	836	if
O	837	841	they
O	842	849	thought
O	850	852	it
O	853	862	indicated
O	863	864	(
O	864	865	"
O	865	870	usual
O	871	875	care
O	875	876	"
O	876	877	)
O	877	878	.

O	879	884	Women
O	885	889	were
O	890	898	followed
O	899	902	for
O	903	904	2
O	904	905	-
O	905	910	years
O	911	928	postrandomization
O	928	929	.

B-intervention-participants	930	931	7
I-intervention-participants	931	932	,
I-intervention-participants	932	935	436
O	936	941	women
O	942	946	were
O	947	955	enrolled
O	956	959	and
B-intervention-participants	960	961	7
I-intervention-participants	961	962	,
I-intervention-participants	962	965	419
O	966	967	(
O	967	969	99
O	969	970	.
O	970	971	8
O	971	972	%
O	972	973	)
O	974	982	screened
O	983	985	in
O	986	998	intervention
O	999	1006	clinics
O	1006	1007	,
O	1008	1014	versus
B-control-participants	1015	1016	8
I-control-participants	1016	1017	,
I-control-participants	1017	1020	419
O	1021	1029	enrolled
O	1030	1033	and
B-control-participants	1034	1035	1
I-control-participants	1035	1036	,
I-control-participants	1036	1039	108
O	1040	1041	(
O	1041	1043	13
O	1043	1044	.
O	1044	1045	1
O	1045	1046	%
O	1046	1047	)
O	1048	1056	screened
O	1057	1059	in
B-control	1060	1067	control
O	1068	1075	clinics
O	1075	1076	.

O	1077	1086	Incidence
O	1087	1093	ratios
O	1094	1095	(
O	1095	1097	IR
O	1097	1098	)
O	1099	1101	of
O	1102	1107	early
O	1107	1108	,
O	1109	1117	advanced
O	1118	1121	and
B-outcome	1122	1125	all
I-outcome	1126	1132	breast
I-outcome	1133	1140	cancers
O	1141	1145	were
O	1146	1147	2
O	1147	1148	.
O	1148	1149	9
O	1150	1151	(
O	1151	1153	95
O	1153	1154	%
O	1155	1157	CI
O	1158	1159	1
O	1159	1160	.
O	1160	1161	1
O	1161	1162	-
O	1162	1163	9
O	1163	1164	.
O	1164	1165	2
O	1165	1166	)
O	1166	1167	,
O	1168	1169	1
O	1169	1170	.
O	1170	1171	0
O	1172	1173	(
O	1173	1174	0
O	1174	1175	.
O	1175	1176	3
O	1176	1177	-
O	1177	1178	3
O	1178	1179	.
O	1179	1180	5
O	1180	1181	)
O	1182	1185	and
O	1186	1187	1
O	1187	1188	.
O	1188	1189	9
O	1190	1191	(
O	1191	1192	0
O	1192	1193	.
O	1193	1194	9
O	1194	1195	-
O	1195	1196	4
O	1196	1197	.
O	1197	1198	1
O	1198	1199	)
O	1200	1202	in
O	1203	1206	the
O	1207	1212	first
O	1213	1214	(
O	1214	1223	screening
O	1223	1224	)
O	1225	1229	year
O	1230	1232	of
O	1233	1236	the
O	1237	1242	trial
O	1242	1243	,
O	1244	1247	and
O	1248	1251	the
O	1252	1262	cumulative
O	1263	1265	IR
O	1266	1269	for
O	1270	1273	all
O	1274	1280	breast
O	1281	1288	cancers
O	1289	1298	converged
O	1299	1301	to
O	1302	1303	1
O	1303	1304	.
O	1304	1305	4
O	1306	1307	(
O	1307	1308	0
O	1308	1309	.
O	1309	1310	7
O	1310	1311	-
O	1311	1312	2
O	1312	1313	.
O	1313	1314	8
O	1314	1315	)
O	1316	1318	by
O	1319	1322	the
O	1323	1326	end
O	1327	1329	of
O	1330	1336	follow
O	1336	1337	-
O	1337	1339	up
O	1340	1341	(
O	1341	1345	Year
O	1346	1347	2
O	1347	1348	)
O	1348	1349	.

B-iv-bin-abs	1350	1358	Eighteen
O	1359	1360	(
B-iv-bin-percent	1360	1362	69
I-iv-bin-percent	1362	1363	.
I-iv-bin-percent	1363	1364	2
I-iv-bin-percent	1364	1365	%
O	1365	1366	)
O	1367	1369	of
B-intervention-participants	1370	1372	26
O	1373	1378	women
O	1379	1383	with
O	1384	1389	early
O	1390	1395	stage
O	1396	1403	disease
O	1404	1407	had
B-outcome	1408	1414	breast
I-outcome	1415	1427	conservation
I-outcome	1428	1435	surgery
I-outcome	1436	1437	(
I-outcome	1437	1440	BCS
I-outcome	1440	1441	)
O	1442	1448	versus
B-cv-bin-abs	1449	1450	6
O	1451	1452	(
B-cv-bin-percent	1452	1454	42
I-cv-bin-percent	1454	1455	.
I-cv-bin-percent	1455	1456	5
I-cv-bin-percent	1456	1457	%
O	1457	1458	)
O	1459	1461	of
B-control-participants	1462	1464	14
O	1465	1470	women
O	1471	1475	with
O	1476	1480	late
O	1480	1481	-
O	1481	1486	stage
O	1487	1494	disease
O	1495	1496	(
O	1496	1497	p
O	1498	1499	=
O	1500	1501	0
O	1501	1502	.
O	1502	1504	02
O	1504	1505	)
O	1505	1506	.

B-iv-bin-abs	1507	1514	Fifteen
O	1515	1516	(
B-iv-bin-percent	1516	1518	68
I-iv-bin-percent	1518	1519	.
I-iv-bin-percent	1519	1520	2
I-iv-bin-percent	1520	1521	%
O	1521	1522	)
O	1523	1525	of
B-intervention-participants	1526	1528	22
O	1529	1534	women
O	1535	1539	with
O	1540	1546	breast
O	1547	1553	cancer
O	1554	1556	in
O	1557	1560	the
O	1561	1573	intervention
O	1574	1579	group
O	1580	1583	had
B-outcome	1584	1587	BCS
O	1588	1594	versus
B-cv-bin-abs	1595	1599	nine
O	1600	1601	(
B-cv-bin-percent	1601	1603	50
I-cv-bin-percent	1603	1604	.
I-cv-bin-percent	1604	1605	0
I-cv-bin-percent	1605	1606	%
O	1606	1607	)
O	1608	1610	of
B-control-participants	1611	1613	18
O	1614	1619	women
O	1620	1622	in
O	1623	1626	the
O	1627	1634	control
O	1635	1640	group
O	1641	1642	(
O	1642	1643	p
O	1644	1645	=
O	1646	1647	0
O	1647	1648	.
O	1648	1650	34
O	1650	1651	)
O	1651	1652	.

O	1653	1657	Well
O	1657	1658	-
O	1658	1666	designed
O	1667	1680	opportunistic
O	1681	1687	clinic
O	1687	1688	-
O	1688	1693	based
O	1694	1700	breast
O	1701	1707	cancer
O	1708	1717	screening
O	1718	1726	programs
O	1727	1730	may
O	1731	1733	be
O	1734	1740	useful
O	1741	1744	for
O	1745	1750	early
O	1751	1757	breast
O	1758	1764	cancer
O	1765	1774	detection
O	1775	1777	in
O	1778	1783	LMICs
O	1783	1784	.
